Alligator Bioscience (Sweden) Insiders
| ATORX Stock | SEK 0.01 0.0003 3.80% |
Alligator Bioscience employs about 53 people. The company is managed by 6 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 8.83 employees per reported executive. Breaking down Alligator Bioscience's management performance can provide insight into the firm performance.
| Peter Ellmark President Vice President Discovery |
Alligator |
Alligator Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.4821) % which means that it has lost $0.4821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0417) %, meaning that it generated substantial loss on money invested by shareholders. Alligator Bioscience's management efficiency ratios could be used to measure how well Alligator Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Alligator Bioscience Workforce Comparison
Alligator Bioscience AB is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 424. Alligator Bioscience retains roughly 53.0 in number of employees claiming about 13% of equities under Health Care industry.
Alligator Bioscience Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Alligator Bioscience Price Series Summation is a cross summation of Alligator Bioscience price series and its benchmark/peer.
Alligator Bioscience Notable Stakeholders
An Alligator Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alligator Bioscience often face trade-offs trying to please all of them. Alligator Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alligator Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Ellmark | Vice President Discovery | Profile | |
| Sumeet MD | Chief Officer | Profile | |
| Malin Carlsson | Ex RD | Profile | |
| Marie Svensson | Chief Officer | Profile | |
| Julie Silber | Director Relations | Profile | |
| Sren Bregenholt | Chief Officer | Profile |
About Alligator Bioscience Management Performance
The success or failure of an entity such as Alligator Bioscience often depends on how effective the management is. Alligator Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alligator management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alligator management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Alligator Bioscience AB develops antibody-based pharmaceuticals for cancer treatment. Alligator Bioscience AB was founded in 2001 and is headquartered in Lund, Sweden. Alligator Bioscience operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 56 people.
Please note, the imprecision that can be found in Alligator Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alligator Bioscience AB. Check Alligator Bioscience's Beneish M Score to see the likelihood of Alligator Bioscience's management manipulating its earnings.
Alligator Bioscience Workforce Analysis
Traditionally, organizations such as Alligator Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alligator Bioscience within its industry.Alligator Bioscience Manpower Efficiency
Return on Alligator Bioscience Manpower
| Revenue Per Employee | 244.2K | |
| Revenue Per Executive | 2.2M | |
| Net Loss Per Employee | 2.7M | |
| Net Loss Per Executive | 23.6M |
Additional Tools for Alligator Stock Analysis
When running Alligator Bioscience's price analysis, check to measure Alligator Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alligator Bioscience is operating at the current time. Most of Alligator Bioscience's value examination focuses on studying past and present price action to predict the probability of Alligator Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alligator Bioscience's price. Additionally, you may evaluate how the addition of Alligator Bioscience to your portfolios can decrease your overall portfolio volatility.